Six Flags stock rises after appointing John Reilly as new CEO
Procept Biorobotics Corp's stock recently reached a 52-week low, hitting a price of 29.78 USD. This milestone reflects a significant downturn for the company, which has experienced a substantial decline in its stock value over the past year. Specifically, Procept Biorobotics has seen its stock price decrease by 65.8% over the last 12 months. Despite this decline, InvestingPro data reveals the company holds more cash than debt on its balance sheet, with a strong current ratio of 8.44, indicating robust liquidity. The drop to this 52-week low underscores the challenges the company faces in the current market environment, as investors react to various factors impacting the medical technology sector. Interestingly, despite the stock's performance, Procept has achieved impressive revenue growth of 50.07% over the last twelve months. According to InvestingPro analysis, the stock appears undervalued based on Fair Value estimates, with analysts setting an average price target that suggests significant upside potential. Discover more insights with the comprehensive Pro Research Report, available for Procept and 1,400+ other US equities.
In other recent news, Procept BioRobotics reported its third-quarter 2025 earnings, exceeding revenue expectations with $83.3 million, marking a 43% increase from the previous year. The company also reported an earnings per share of -$0.38, which was slightly better than the anticipated -$0.41. Following this earnings announcement, TD Cowen adjusted its price target for Procept BioRobotics to $50, maintaining its previous stock rating. Similarly, Leerink Partners lowered its price target to $55 from $65, while keeping an Outperform rating. According to Leerink Partners, the company achieved a 3% revenue beat in the third quarter, with U.S. system sales surpassing expectations by reaching 57 units against a forecast of 52 units. Procept BioRobotics also maintained its 2025 sales guidance and introduced 2026 guidance, which aligns with Street estimates at the higher end. These developments reflect the company's recent performance and market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.